Abstract
During the past 10 years, substantial progress has been made in the discovery and development of small molecule glutamate carboxypeptidase II (GCP II) inhibitors. These inhibitors have provided the necessary tools to investigate the physiological role of GCP II as well as the potential therapeutic benefits of its inhibition in neurological disorders of glutamatergic dysregulation. This review article details key GCP II inhibitors discovered in the last decade and important findings from preclinical and clinical studies.
MeSH terms
-
Animals
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / therapeutic use
-
Drug Design
-
Glutamate Carboxypeptidase II / antagonists & inhibitors*
-
Glutamate Carboxypeptidase II / chemistry
-
Glutarates / chemistry
-
Glutarates / therapeutic use
-
Humans
-
Molecular Structure
-
Neuroprotective Agents / chemistry
-
Neuroprotective Agents / therapeutic use
-
Organophosphorus Compounds / chemistry
-
Organophosphorus Compounds / therapeutic use
-
Phosphinic Acids / chemistry
-
Phosphinic Acids / therapeutic use
-
Structure-Activity Relationship
-
Sulfhydryl Compounds / chemistry
-
Sulfhydryl Compounds / therapeutic use
Substances
-
2-(3-mercaptopropyl)pentanedioic acid
-
2-(phosphonomethyl)pentanedioic acid
-
Antineoplastic Agents
-
Glutarates
-
Neuroprotective Agents
-
Organophosphorus Compounds
-
Phosphinic Acids
-
Sulfhydryl Compounds
-
Glutamate Carboxypeptidase II